TEST

BenevolentAI is a clinical-stage drug discovery company seeking to combine artificial intelligence and machine learning with science to decipher complex disease biology, generate new insights and discover more effective medicines. The company’s computational R&D platform spans each step of the drug discovery process, with a focus on novel disease targets discovery.

BenevolentAI

TEST

Pulmonx focuses on minimally invasive treatments for severe lung disease. The company’s platforms are designed to assess and treat patients with severe emphysema and chronic obstructive pulmonary disease who, despite medical management, are still symptomatic. Pulmonx completed its IPO on the Nasdaq stock market in October 2020.

Pulmonx

TEST

Arbor Biotechnologies is a biotechnology company that aims to discover and develop the next generation of genetic medicines based on wholly owned genomic editors discovered from its machine learning/AI driven discovery platform.

Arbor Biotechnologies

TEST

Endeavor BioMedicines is a clinical-stage precision medicine company that targets the core drivers of multiple terminal diseases, including oncology and fibrosis. The Company seeks to combine advancements in technology with an evolving understanding of terminal diseases in order to develop best-in-class medicines with the potential to reverse the most severe health conditions.

Endeavor BioMedicines

TEST

Shoreline Biosciences is a biotechnology company developing genetically engineered induced pluripotent stem cell (iPSC)-derived allogeneic natural killer and macrophage immunotherapies for the treatment of cancer.

Shoreline Biosciences

TEST

Transcarent is a digital health company focused on employee health benefits, aiming to improve the both the quality of care and reduce inefficiency in the existing healthcare system.

Transcarent

TEST

WuXi Biologics is a global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a one-stop service offering and strong value proposition to its global clients. WuXi Biologics completed its IPO on the Hong Kong stock exchange in June 2017.

WuXi Biologics

TEST

WuXi AppTec provides a portfolio of R&D and manufacturing services that enable companies in the global pharmaceutical, biotechnology and medical device industries to advance discoveries and deliver treatments to patients. WuXi AppTec helps its partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec completed its IPO on the Hong Kong stock exchange in December 2018.

WuXi AppTec

TEST

Vida Health is a digital management company focused on developing a proprietary technology platform that provides chronic disease, wellness and mental/behavioral health management solutions.

Vida Health

TEST

Syapse aims to use real-world evidence brought by Syapse Learning Health Network to improve the outcomes of cancer patients through improved precision medicine. Syapse and its partners are working towards a future where all cancer patients have access to the quality of care they need.

Syapse